Utilization of HIV/AIDS treatment services: Comparing injecting drug users and other clients

Cadernos de Saude Publica

Volumn 22, Issue 4, 2006, Pages 803-813

  De Melo, Angelita Cristine ^a   Caiaffa, Waleska Teixeira ^a   César, Cibele Comini ^a   Dantas, Ricardo Vieira ^a   Couttolenc, Bernard François ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acquired Immunodeficiency Syndrome; Health Services; HIV; Street Drugs

Indexed keywords

EID: 33646233172     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/s0102-311x2006000400019     Document Type: Article

References (42)

1. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997; 277:1962-9.
2. Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999; 22:369-78.
3. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15:1115-23.
4. Kahn JG, Zhang X, Cross JG, Palacio H, Birkhead GS, Morin SF. Access to and use of HIV antiretroviral therapy: variation by race/ethnicity in two public insurance programs in the U.S. Public Health Rep 2002; 117:252-62.
5. Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, et al. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS 2004; 18:2333-7.
6. Teixeira PR, Vitoria MA, Barcarolo J. Antiretroviral treatment in resource-poor settings: the Brazilian experience. AIDS 2004; 18 Suppl 3:S5-7.
7. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995; 333:751-6.
8. Schoenbaum EE, Lo Y, Floris-Moore M. Predictors of hospitalization for HIV-positive women and men drug users, 1996-2000. Public Health Rep 2002; 117:60-7.
9. Waidmann TA, Rajan S. Race and ethnic disparities in health care access and utilization: an examination of state variation. Med Care Res Rev 2000; 57 Suppl 1:55-84.
10. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman J, et al. Variations in the care of HIV-infected adults in the United States: Results From the HIV Cost and Services Utilization Study. JAMA 1999; 281:2305-15.
11. Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 1999; 21:114-9.
12. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 12:547-9.
13. Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA 1997; 278:63-5.
14. Vlahov D, Celentano DD. Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death. Cad Saúde Pública 2006; 22:705-31.
15. Sollitto S, Mehlmana M, Youngner S, Lederman MM. Should physicians withhold highly active antiretroviral therapies from HIV-AIDS patients who are thought to be poorly adherent to treatment? AIDS 2001; 15:153-9.
16. Nemes MIB, Carvalho HB, Souza MFM. Antiretroviral therapy adherence in Brazil. AIDS 2004; 18 Suppl 3:S15-20.
17. Carvalho CV, Duarte DB, Merchán-Hamann E, Bicudo E, Laguardia J. Determinantes da aderência à terapia anti-retroviral combinada em Brasília, Distrito Federal, Brasil, 1999-2000. Cad Saúde Pública 2003; 19:593-604.
18. Freeman RC, Rodriguez GM, French JF. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. AIDS Educ Prev 1995; 8:58-71.
19. Pechansky F, Inciardi JA, Surratt H, Lima AFBS, Kessler FP, Soibelman M, et al. Estudo sobre as características de usuários de drogas injetáveis que buscam atendimento em Porto Alegre, RS. Rev Bras Psiquiatr 2000; 22:164-71.
20. Couttolenc BF, Caiaffa WT, Pluciennick AMA, Santos, NJ, Waldvogel B, Marques HHS, et al. Análise de custo e impacto da terapia anti-retroviral. São Paulo: Faculdade de Saúde Pública, Universidade de São Paulo/Coordenação Nacional DST/AIDS, Organização das Nações Unidas para a Educação, a Ciência e a Cultura; 2004.
21. Ministério da Saúde. Informações de saúde: população residente - Brasil. http://tabnet.datasus.gov.br/cgi/tabcgi.exe?ibge/cnv/popbr.def (accessed on 25/Jun/2005).
22. Ministério da Saúde. Dados e pesquisas em DST e AIDS: dados de AIDS. http://www.AIDS.gov.br/tabnet_AIDS.htm (accessed on 25/Jun/2005).
23. Ministério da Saúde. Informações de saúde: população residente - Brasil. http://www.AIDS.gov.br/tabnet_AIDS.htm (accessed on 13/Mar/2005).
24. Lwanga SK, Lemeshow S. Sample size determination in health studies: a practical manual. Geneva: World Health Organization; 1991.
25. Ministério da Saúde. Modificação da hierarquização das categorias de exposição dos casos de aids. Boletim Epidemiológico AIDS 2002; 1:45.
26. Ministério da Saúde. Consenso sobre terapia anti-retroviral em adultos: 1996. http://www.AIDS.gov.br (accessed on 10/Nov/2004).
27. Ministério da Saúde. Consenso sobre terapia anti-retroviral em adultos e adolescentes infectados pelo HIV: 1997. http://www.AIDS.gov.br (accessed on 10/Nov/2004).
28. Ministério da Saúde. Consenso sobre terapia anti-retroviral em adultos e adolescentes infectados pelo HIV: 1998. http://www.AIDS.gov.br (accessed on 10/Nov/2004).
29. Ministério da Saúde. Consenso sobre terapia anti-retroviral em adultos e adolescentes infectados pelo HIV: 2000. http://www.AIDS.gov.br (accessed on 10/Nov/2004).
30. Fisher LD, Belle GV. Biostatistics: a metodology for health sciences. New York: John Wiley & Sons; 1993.
31. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. New York: Lifetime Learning Publications, Van Nostrand Reinhold Publishing Co.; 1982.
32. Junghans C, Low N, Chan P, Witschi A, Vernazza P, Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999; 13:2547-54.
33. Caiaffa WT, Mingoti SA, Proietti FA, Carneiro-Proietti AB, Silva RC, Lopes AC, et al. Estimation of the number of injecting drug users attending an outreach syringe-exchange program and infection with human immunodeficiency virus (HIV) and hepatitis C virus: the AjUDE-Brasil project. J Urban Health 2003; 80:106-14.
34. Boily MC, Bastos FI, Desai K, Masse B. Changes in the transmission dynamics of the HIV epidemic after the wide-scale use of antiretroviral therapy could explain increases in sexually transmitted infections: results from mathematical models. Sex Transm Dis 2004; 31:100-13.
35. Barnes PM, Adams PF, Schiller JS. Summary health statistics for the U.S. population: National Health Interview Survey, 2001. Vital Health Stat 10 2003; (217):1-82.
36. Pleis JR, Schiller JS, Benson V. Summary health statistics for U.S. adults: National Health Interview Survey, 2000. Vital Health Stat 10 2003; (215):1-132.
37. Acurcio FA, Cesar CC, Guimarães, MDC. Health care utilization and survival among patients with AIDS in Belo Horizonte, Minas Gerais, Brazil. Cad Saúde Pública 1998; 14:811-20.
38. Organización Mundial de la Salud. Expansión del Tratamiento Antirretroviral en los Entornos con Recursos Limitados: directrices para un enfoque de salud pública - Resumen de orientación. Geneva: Organización Mundial de la Salud; 2004.
39. Queiroz IS. Adoção de ações de redução de danos direcionadas aos usuários de drogas: concepções e valores de equipes de Programa de Saúde da Família [Dissertação de Mestrado]. Belo Horizonte: Faculdade de Filosofia e Ciências Humanas, Universidade Federal de Minas Gerais; 2005.
40. Cardoso MN, Caiaffa WT, Mingoti SA; Projeto AjUDE-Brasil II. AIDS incidence and mortality in injecting drug users: the AjUDE-Brasil II Project. Cad Saúde Pública 2006; 22:827-37.
41. Ferreira AD, Caiaffa WT, Bastos FI, Mingoti SA; Projeto AjUDE-Brasil II. Injecting drug users who are (un)aware of their HIV serostatus: findings from the multi-center study AjUDE-Brasil II. Cad Saúde Pública 2006; 22:815-26.
42. Aceijas C, Stimson GV, Hickman M, Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 2004; 18: 2295-303.